{{Infobox_gene}}
'''ADAMTS13'''（'''''a''' '''d'''isintegrin '''a'''nd '''m'''etalloproteinase with a '''t'''hrombo'''s'''pondin type 1 motif, member '''13'''''），又稱'''溫韋伯氏因子裂解酶'''（von Willebrand factor-cleaving protease，VWFCP）是一種含[[锌|锌]]的[[金屬蛋白酶|金屬蛋白酶]]。ADAMTS13可以裂解一種稱為{{tsl|en|von Willebrand factor|溫韋伯氏因子}}（vWf）的大型[[凝血因子|凝血因子]]。為一種主要由肝臟星狀細胞(stellate cell)製造的蛋白酶，少量由血管內皮細胞、血小板、腎臟足細胞及腎小管上皮細胞分泌<ref>[Turner N, Nolasco L, Tao Z, et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost. 2006;4:1396–1404.]</ref>，在人體與動物實驗中皆發現受試者接受部分肝切除手術後，ADAMTS13的活性會下降至正常值的30~40%，可見肝臟對ADAMTS13的製造具有重要的貢獻。本酵素存在於[[血液|血液]]之中，降解vWf多聚體，以降低它們的活性<ref name=Levy2005>{{cite journal |vauthors=Levy GG, Motto DG, Ginsburg D |title=ADAMTS13 turns 3 |journal=Blood |volume=106 |issue=1 |pages=11–7 |year=2005 |pmid=15774620 |doi=10.1182/blood-2004-10-4097 |url=http://bloodjournal.hematologylibrary.org/cgi/content/full/106/1/11 |author= |access-date=2016-12-20 |archive-url=https://web.archive.org/web/20100824080555/http://bloodjournal.hematologylibrary.org/cgi/content/full/106/1/11 |archive-date=2010-08-24 |dead-url=yes }}</ref>。

==遺傳學==
''ADAMTS13''[[基因|基因]]存在於第九對[[染色体|染色体]]（9q34）上<ref name=Levy2005/>。

==發現==
自1982年時，人們就知道遺傳性{{tsl|en|thrombotic thrombocytopenic purpura|血栓性血小板減少性紫癜}}（TTP，一種{{tsl|en|microangiopathic hemolytic anemia|微血管病性溶血性貧血}}）患者的血漿中，存在異常巨大的溫韋伯氏因子多聚體（ULVWF）<ref name=Levy2005/>。

1994年，發現在高剪力下時，有一種血漿金屬酶會從vWF第1605位的[[酪氨酸|酪氨酸]]及1606位的[[甲硫氨酸|甲硫氨酸]]間切割。1996年，兩個獨立研究團隊分別發現該酵素。自接下來的兩年，同樣的兩個團隊證明了vWF裂解酶與小血管的[[血小板|血小板]][[血栓|血栓]]生成相關。此外他們還報導了在大部分非遺傳性TTP患者身上，能發現對抗ADAMTS13的[[IgG|IgG]][[抗体|抗体]]<ref name=Levy2005/>。

==蛋白質組學==
{{tsl|en|ADAMTS|ADAMTS家族}}目前共已知有19種蛋白質，ADAMTS13屬於其中一員，與其他金屬蛋白酶族同樣有一個14個相異的結構域組成的結構，包括金屬蛋白酶(metalloprotease)、解整合素(disintegrin)、TSP1(first thrombospondin type 1 repeat)和間隔域(spacer domain) ，但ADAMTS13並不具備穿膜蛋白結構 ，因此其不存在細胞膜上，而是隨著血液循環在大小血管內作用。該家族的蛋白質擁有蛋白酶結構域，可以水解蛋白質，鄰近則有{{tsl|en|disintegrin|解聚素}}結構域，且含有多個{{tsl|en|thrombospondin|血小板反應蛋白}}結構域。ADAMTS13含有8個血小板反應蛋白結構域，且無輸水穿膜段，所以該蛋白並非膜蛋白<ref name=Levy2005/>。

==臨床角色==
ADAMTS13缺乏症最早發現於{{tsl|en|Upshaw Schulman Syndrome|Upshaw Schulman Syndrome}}，為一種復發性遺傳性{{tsl|en|thrombotic thrombocytopenic purpura|血栓性血小板減少性紫癜}}。當時學界認為該病屬於一種[[自體免疫|自體免疫]]疾病，因為該疾病使用[[血漿置換|血漿置換]]及IgG抑制劑。在ADAMTS13發現後，研究人員發現這些自體抗體會對抗該蛋白上的[[抗原表位|抗原表位]]<ref name=Levy2005/><ref>{{cite journal |author=Tsai HM |title=Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura |journal=J. Am. Soc. Nephrol. |volume=14 |issue=4 |pages=1072–81 |year=2003 |pmid=12660343 |url=http://jasn.asnjournals.org/cgi/content/full/14/4/1072 |doi=10.1097/01.ASN.0000060805.04118.4C |access-date=2016-12-20 |archive-date=2007-10-20 |archive-url=https://web.archive.org/web/20071020123146/http://jasn.asnjournals.org/cgi/content/full/14/4/1072 |dead-url=yes }}</ref><ref>{{cite journal |vauthors=Furlan M, Lämmle B |title=Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease |journal=Best Pract Res Clin Haematol |volume=14 |issue=2 |pages=437–54 |year=2001 |pmid=11686108 |doi=10.1053/beha.2001.0142}}</ref>。ADAMTS13具有裂解溫韋伯氏因子多聚體(UL-VWFM)並降低溫韋伯氏因子活性的功能 ，能抑止血小板堆積於微血管形成血栓。<ref>[Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 2005, 106 (1): 11–7]</ref>由血管內皮細胞分泌的ADAMTS13，可能負責大部分新生溫韋伯氏因子多聚體的裂解，以達到即刻性抑止血栓形成的作用。當ADAMTS13受到自身抗體的攻擊而導致活性下降(小於正常活性10%)，即可能造成呈現巨分子狀態的溫韋伯氏因子(也就是溫韋伯氏因子多聚體)沉積後黏附於血管內皮細胞表層，促使微小血管中血小板凝集，使血液中游離的血小板數量不足，同時血管中的纖維蛋白增加亦破壞紅血球結構，形成不正常型態的血球 (例如:裂細胞Schistocyte)與發生溶血現象，導致產生獲得性血栓性血小板減少性紫斑症的臨床症狀。
    研究中發現ADAMTS13低下除了與獲得性血栓性血小板減少性紫斑症的形成密切相關外，在其他栓塞性微血管病變(thrombotic microangiopathy,TMA)中ADAMTS13有不同程度的下降<ref>[Martin K, Borgel D, Lerolle N, et al. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med. 2007;35(10):2375-2382.]</ref> ，在敗血症、惡性高血壓病患及自體免疫患者中也有發生相似的變化<ref>[Farkas P, Csuka D, Mikes B, et al. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. Immunobiology. 2017;222(2):119-127.]</ref><ref>[Khanal N, Dahal S, Upadhyay S, Bhatt VR, Bierman PJ. Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2015;6(3):97-102..]</ref> ，因此合理的推論ADAMTS13活性下降雖然不一定成為直接造成上述疾病的成因，但極有可能在這些病症中擔任促成因子的角色。


<!-- Especially since the link between [[主動脈瓣狹窄|aortic valve stenosis]] and [[肠道血管发育不良|angiodysplasia]] was proven to be due to high [[剪應力|shear stress]] ({{tsl|en|Heyde's syndrome||Heyde's syndrome}}), it has been accepted that increased exposure of vWf to ADAMTS13 due to various reasons would predispose to [[出血|bleeding]] by causing increased degradation of vWf. This phenomenon is characterised by a form of [[血管性血友病|von Willebrand disease]] (type 2a).<ref name=Levy2005/> -->

==參見==
* {{tsl|en|ADAMTS5||ADAMTS5}} <!--another ADAMTS with a wiki page-->

==參考文獻==
{{reflist}}

==延伸閱讀==
{{refbegin | 2}}
* Furlan M, Lammle B. ''Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.'' Best Pract Res Clin Haematol 2001;14:437-54. PMID 11686108.
* Tsai HM. ''Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.'' J Am Soc Nephrol 2003;14:1072-81. PMID 12660343.
{{PBB_Further_reading
| citations =
*{{cite journal  | author=Tang BL |title=ADAMTS: a novel family of extracellular matrix proteases. |journal=Int. J. Biochem. Cell Biol. |volume=33 |issue= 1 |pages= 33–44 |year= 2001 |pmid= 11167130 |doi=10.1016/S1357-2725(00)00061-3  }}
*{{cite journal  |vauthors=Fujimura Y, Matsumoto M, Yagi H |title=Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. |journal=Int. J. Hematol. |volume=75 |issue= 1 |pages= 25–34 |year= 2002 |pmid= 11843286 |doi=10.1007/BF02981975  |display-authors=etal}}
*{{cite journal  |vauthors=Zheng X, Majerus EM, Sadler JE |title=ADAMTS13 and TTP. |journal=Curr. Opin. Hematol. |volume=9 |issue= 5 |pages= 389–94 |year= 2003 |pmid= 12172456 |doi=10.1097/00062752-200209000-00001  }}
*{{cite journal  | author=Tsai HM |title=Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. |journal=J. Mol. Med. |volume=80 |issue= 10 |pages= 639–47 |year= 2003 |pmid= 12395148 |doi= 10.1007/s00109-002-0369-8 }}
*{{cite journal  | author=Tsai HM |title=Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. | url=https://archive.org/details/sim_arteriosclerosis-thrombosis-and-vascular-biology_2003-03_23_3/page/388 |journal=Arterioscler. Thromb. Vasc. Biol. |volume=23 |issue= 3 |pages= 388–96 |year= 2003 |pmid= 12615692 |doi= 10.1161/01.ATV.0000058401.34021.D4 }}
*{{cite journal  | author=Tsai HM |title=Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. |journal=J. Thromb. Haemost. |volume=1 |issue= 4 |pages= 625–31 |year= 2003 |pmid= 12871390 |doi=10.1046/j.1538-7836.2003.00169.x  }}
*{{cite journal  | author=Remuzzi G |title=Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. |journal=J. Thromb. Haemost. |volume=1 |issue= 4 |pages= 632–4 |year= 2003 |pmid= 12871391 |doi=10.1046/j.1538-7836.2003.00170.x  }}
*{{cite journal  | author=Moake JL |title=von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. |journal=Semin. Hematol. |volume=41 |issue= 1 |pages= 4–14 |year= 2004 |pmid= 14727254 |doi=10.1053/j.seminhematol.2003.10.003  }}
*{{cite journal  |vauthors=López JA, Dong JF |title=Cleavage of von Willebrand factor by ADAMTS-13 on endothelial cells. |journal=Semin. Hematol. |volume=41 |issue= 1 |pages= 15–23 |year= 2004 |pmid= 14727255 |doi=10.1053/j.seminhematol.2003.10.004  }}
*{{cite journal  |vauthors=Plaimauer B, Scheiflinger F |title=Expression and characterization of recombinant human ADAMTS-13. |journal=Semin. Hematol. |volume=41 |issue= 1 |pages= 24–33 |year= 2004 |pmid= 14727256 |doi=10.1053/j.seminhematol.2003.10.006  }}
*{{cite journal  |vauthors=Kokame K, Miyata T |title=Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. |journal=Semin. Hematol. |volume=41 |issue= 1 |pages= 34–40 |year= 2004 |pmid= 14727257 |doi=10.1053/j.seminhematol.2003.10.002  }}
*{{cite journal  |vauthors=Schneppenheim R, Budde U, Hassenpflug W, Obser T |title=Severe ADAMTS-13 deficiency in childhood. |journal=Semin. Hematol. |volume=41 |issue= 1 |pages= 83–9 |year= 2004 |pmid= 14727263 |doi=10.1053/j.seminhematol.2003.10.007  }}
*{{cite journal  |vauthors=Kremer Hovinga JA, Studt JD, Lämmle B |title=The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). |journal=Pathophysiol. Haemost. Thromb. |volume=33 |issue= 5-6 |pages= 417–21 |year= 2005 |pmid= 15692254 |doi= 10.1159/000083839 }}
*{{cite journal  |vauthors=Levy GG, Motto DG, Ginsburg D |title=ADAMTS13 turns 3. |journal=Blood |volume=106 |issue= 1 |pages= 11–7 |year= 2005 |pmid= 15774620 |doi= 10.1182/blood-2004-10-4097 }}
*{{cite journal  | author=George JN |title=ADAMTS13, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome. |journal=Curr. Hematol. Rep. |volume=4 |issue= 3 |pages= 167–9 |year= 2005 |pmid= 15865866 |doi=  }}
*{{cite journal  | author=Dong JF |title=Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. |journal=J. Thromb. Haemost. |volume=3 |issue= 8 |pages= 1710–6 |year= 2005 |pmid= 16102037 |doi= 10.1111/j.1538-7836.2005.01360.x }}
*{{Cite journal | last1 = Matsukawa | first1 = M. | last2 = Kaikita | first2 = K. | last3 = Soejima | first3 = K. | last4 = Fuchigami | first4 = S. | last5 = Nakamura | first5 = Y. | last6 = Honda | first6 = T. | last7 = Tsujita | first7 = K. | last8 = Nagayoshi | first8 = Y. | last9 = Kojima | first9 = S. | last10 = Shimomura | first10 = H. | last11 = Sugiyama | first11 = S. | last12 = Fujimoto | first12 = K. | last13 = Yoshimura | first13 = M. | last14 = Nakagaki | first14 = T. | last15 = Ogawa | first15 = H. | title = Serial Changes in von Willebrand Factor-Cleaving Protease (ADAMTS13) and Prognosis After Acute Myocardial Infarction | doi = 10.1016/j.amjcard.2007.03.095 | journal = The American Journal of Cardiology | volume = 100 | issue = 5 | pages = 758–763 | year = 2007 | pmid =  17719316| pmc = }}
}}
{{refend}}

==外部連結==
* The [[MEROPS|MEROPS]] online database for peptidases and their inhibitors: [http://merops.sanger.ac.uk/cgi-bin/merops.cgi?id=M12.241 M12.241]{{Dead link}}
* {{OMIM|274150}}
* [https://web.archive.org/web/20041127134912/http://spd.cbi.pku.edu.cn/spd_pro.php?id=nm_139025 Secreted protein database] entry
* {{UCSC gene info|ADAMTS13}}

{{Metalloendopeptidases}}
{{Enzymes}}
{{Portal bar|Molecular and Cellular Biology|border=no}}

<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{PBB_Controls
| update_page = yes
| require_manual_inspection = no
| update_protein_box = yes
| update_summary = no
| update_citations = yes
}}

[[Category:EC_3.4.24|Category:EC 3.4.24]]
{{tsl|en|Category:ADAMTS||Category:ADAMTS}}

{{DEFAULTSORT:Adamts13}}

[[Category:EC_3.4.24|Category:EC 3.4.24]]